What is Amyris?
Headquartered in Emeryville, California, with significant operational presence in Brazil, Amyris operates as an integrated renewable products company. The firm utilizes advanced bioscience to engineer microorganisms that act as living factories, producing specialty ingredients for the cosmetics, fragrance, and health sectors. By replacing traditional, petroleum-based chemical processes with bio-based alternatives, Amyris enables businesses to achieve sustainable growth while maintaining high performance standards.
The company's market position is defined by its unique ability to bridge the gap between laboratory-scale innovation and industrial-scale manufacturing. Through its integrated platform, Amyris addresses the growing demand for clean, traceable, and environmentally responsible supply chains, effectively disrupting legacy chemical industries with its proprietary fermentation-based solutions.
How much funding has Amyris raised?
Amyris has raised a total of $775.6M across 14 funding rounds:
Debt
$21.7M
Debt
$57.6M
Multiple Rounds
$59.5M
Debt
$19.1M
Multiple Rounds
$317M
Debt
$80M
Debt
$50M
Debt (2014): $21.7M, investors not publicly disclosed
Debt (2015): $57.6M, investors not publicly disclosed
Debt (2016): $20M, investors not publicly disclosed
Debt (2016): $6M, investors not publicly disclosed
Debt (2016): $8.5M, investors not publicly disclosed
Debt (2016): $25M, investors not publicly disclosed
Debt (2017): $19.1M, investors not publicly disclosed
Private Equity (2020): $112M backed by Foris Ventures
Debt (2020): $5M with participation from PPP
Share Placement (2020): $200M, investors not publicly disclosed
Debt (2022): $80M supported by Foris Ventures
Debt (2023): $50M, investors not publicly disclosed
Key Investors in Amyris
Foris Ventures
Foris Ventures is a private investment firm that focuses on supporting high-growth companies within the biotechnology and sustainable technology sectors.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed institutional investor participating in the funding round to support the company's long-term growth objectives.
What's next for Amyris?
Looking ahead, the recent capital injection is expected to accelerate the optimization of Amyris's manufacturing processes and support the commercialization of its expanding product pipeline. As the company navigates the complexities of the renewable chemicals market, the focus will likely shift toward operational efficiency and the scaling of its consumer-facing brands. By maintaining a robust balance sheet, Amyris is well-positioned to navigate market volatility while continuing to pioneer advancements in synthetic biology. The strategic deployment of these funds will be critical in sustaining the company's competitive advantage as it seeks to capture a larger share of the global specialty ingredients market, ultimately driving long-term value for stakeholders through sustainable innovation.
See full Amyris company page
